Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

Cited 27 time in Web of Science Cited 25 time in Scopus
Park, Jong-Chan; Han, Sun-Ho; Cho, Hyun Jin; Byun, Min Soo; Yi, Dahyun; Choe, Young Min; Kang, Seokjo; Jung, Eun Sun; Won, Su Jin; Kim, Eun Hye; Kim, Yu Kyeong; Lee, Dong Young; Mook-Jung, Inhee
Issue Date
BioMed Central
Alzheimer's Research & Therapy, 9(1):20
Alzheimer’s diseaseβ-amyloidPlasma AβBlood-based biomarkerMPPPittsburgh-compound B positron emission tomography
Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimers disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks of AD pathogenesis in the brain. However, the association between plasma Aβ levels and AD diagnosis is still unclear due to the instability and inaccurate measurements of plasma Aβ levels in the blood of patients with AD. If a consistent value of plasma Aβ from the blood can be obtained, this might help determine whether plasma Aβ is a potential biomarker for AD diagnosis.

We predicted the brain amyloid deposit by measuring the plasma Aβ levels. This cross-sectional study included 353 participants (215 cognitively normal, 79 with mild cognitive impairment, and 59 with AD dementia) who underwent Pittsburgh-compound B positron emission tomography (PiB-PET) scans. We treated a mixture of protease inhibitors and phosphatase inhibitors (MPP) and detected plasma Aβ42 and Aβ40 (MPP-Aβ42 and MPP-Aβ40) in a stable manner using xMAP technology.

MPP-Aβ40 and MPP-Aβ42/40 (MPP-Aβs) were significantly different between subjects with positive amyloid deposition (PiB+) and those with negative amyloid deposition (PiB–) (P < 0.0001). Furthermore, MPP-Aβ40 (P < 0.0001, r = 0.23) and MPP-Aβ42/40 ratio (P < 0.0001, r = –0.23) showed significant correlation with global PiB deposition (standardized uptake value ratio). In addition, our integrated multivariable (MPP-Aβ42/40, gender, age, and apolipoprotein E genotypes) logistic regression model proposes a new standard for the prediction of cerebral amyloid deposition.

MPP-Aβ might be one of the potential blood biomarkers for the prediction of PiB-PET positivity in the brain.
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Biomedical Sciences (대학원 의과학과)Journal Papers (저널논문_의과학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.